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 Holocarboxylase synthetase (HCS) is a chromatin protein that is essential for 
mediating the covalent binding of biotin to histones. Biotinylation of histones plays 
crucial roles in the repression of genes and repeats in the human genome. The objective 
of this project was to determine genomic binding sites of holocarboxylase synthetase 
(HCS) in the human chromatin of breast cell lines using an antibody independent 
technology. We tested the feasibility of DNA adenine methyltransferase identification 
(DamID) technology to map HCS binding sites in human mammary cell lines. Full-length 
HCS was fused to Dam for subsequent transfection into breast cancer (MCF-7) and 
normal breast (MCF-10A) cells. HCS docking sites in chromatin were identified by using 
the unique adenine methylation sites established by Dam in the fusion construct; docking 
sites were unambiguously identified using methylation sensitive digestion, cloning, and 
sequencing. Fifteen novel HCS binding sites were identified and included sequences 
within genes coding for inositol polyphosphate-5-phosphatase A, corticotropin hormone 
precursor, myosin heavy chain 9 non-muscle, cadherins 8 and 11, prolactin, leptin 
precursor, schwannomin 1, apoptosis inhibitor, netrin-G1 ligand, neuron navigator, SRY-
box4, purinergic receptor, and CUB and sushi domains.  We conclude that DamID is a 
useful technology to map HCS binding sites in human chromatin and propose that the 
entire set of HCS binding sites could be mapped by combining DamID with microarray 
technology. 
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Chapter 1 
 
1.1 Introduction 
 
 The objective of this project was to monitor native binding sites of 
holocarboxylase synthetase [HCS], a chromatin protein, in human breast cell lines using 
an antibody independent technology. This project utilizes the DNA adenine 
methyltransferase identification [DamID] technology developed by Dr. Bas van Steensel 
from Netherland‟s Cancer Research Institute [1]. Studies conducted in this project verify 
the DamID technology in breast cancer and human breast cell lines. The project 
eliminates the use of ChIP assays, a commonly used technology to study DNA-protein 
interactions and epigenetic mechanisms. ChIP assays depend heavily on specificity of 
antibodies and large cell numbers and hence cannot be used to study DNA-protein 
interactions in small populations of cells, such as oocytes [2, 3]. The verification of 
DamID technology in human breast tissues confirms the principle behind the technology. 
Future work with this technology could enable the study of chromatin proteins and 
aberrant epigenetic marks in oocytes that are artificially cultured for a period of 2-3 days 
prior to in-vitro fertilization. 
1.2 Background 
 
 1.2.1 Epigenetics 
 
Epigenetics is defined as „the study of heritable changes in gene expression that 
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occur independent of changes in the primary DNA sequence‟ [4]. Most of these heritable 
changes are established during differentiation and are stably maintained through multiple 
cycles of cell division, enabling cells to have distinct identities while containing the same 
genetic information. This heritability of gene expression patterns is mediated by 
epigenetic modifications, which include methylation of cytosine bases in DNA, and 
posttranslational modifications, such as methylation, acetylation, ubiquitylation, 
phosphorylation, and biotinylation, of histone proteins [5, 6]. The complement of these 
modifications, collectively referred to as the epigenome, provides a mechanism for 
cellular diversity by regulating what genetic information can be accessed by cellular 
machinery. Failure of the proper maintenance of heritable epigenetic marks can result in 
inappropriate activation or inhibition of various signaling pathways and lead to disease 
states such as cancer [4, 7]. 
DNA methylation is perhaps the most extensively studied epigenetic modification 
in mammalian cell lines [8, 9]. It provides a stable gene silencing mechanism that plays 
an important role in regulating gene expression and chromatin architecture, in association 
with histone modifications and other chromatin associated proteins. In mammals, DNA 
methylation primarily occurs by the covalent modification of cytosine residues in CpG 
dinucleotides [8]. CpG islands are preferentially located at the 5‟ end of genes and 
occupy 60% of human gene promoters [8]. Methylation of these gene promoters is 
generally not detected in normal tissues but hypermethylation of CpG islands resulting in 
a loss of gene function is a common feature of almost every type of cancer. CpG gene 
promoter is among the most frequently methylated sites in human breast cancer and its 
methylation leads to silencing of RASSF1A and several other genes [10]. A screen of 
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paired invasive ductal carcinomas with adjacent normal tissues and additional breast 
samples obtained from healthy individuals identified several loci that are preferentially 
methylated in tumor versus normal tissue; a careful analysis of three such genes 
[CYP26A1, KCNAB1, and SNCA] suggests that their methylation in the primary tumors 
can be associated with methylation in the adjacent normal tissues [10].  
In addition to epigenetic modification of the DNA, the histone N-terminal tails are 
crucial to maintaining chromatin stability and they are subject to numerous epigenetic 
modifications.  Most modifications have some role to play in transcriptional regulation 
and so each has the potential to be oncogenic if deregulated deposition leads, for 
example, to loss of expression of a tumour suppressor gene [6, 11]. Histone 
acetyltransferase [HATs], enzyme responsible for histone acetylation, tend to be 
transcriptional activators whereas histone deacetylases [HDACs] tend to be 
transcriptional repressors.  Many HAT genes are altered in some way in a variety of 
cancers [6, 11]. For instance, the p300 HAT gene is mutated in gastrointestinal tumours 
[6]. Similarly, methylation of histone proteins has also been associated with various types 
of cancer, including lymphoma and gastrointestinal cancer [12]. Lysine 
methyltransferases that target histone N-terminal tails contain a so-called SET 
domain.  This domain possesses lysine methyltransferase activity and numerous SET 
domain-containing proteins are implicated in cancer [12, 13].  One example is the Suv39 
family of enzymes that catalyse methylation of H3K9.  Transgenic mice devoid of these 
enzymes are susceptible to cancer, especially B cell lymphomas [13]. Aurora kinases that 
perform phosphorylation of histone H3 at serine residues 10, and 28 during mitosis, a 
crucial stage of cell cycle, has been linked to pancreatic cancer [11, 13, 14]. 
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Ubiqutination of histones H2A and H2B at aberrant amino acid site has been assocaited 
with lung cancer [15].  
1.2.2 Holocarboxylase Synthetase and Biotinylation 
A less investigated epigenetic modification of the histone proteins is biotinylation. 
There is increasing evidence that histones are covalently modified by the vitamin biotin, 
mediated by holocarboxylase synthetase [HCS] and biotinidase [16, 17, 18, 19, 20 ]. 
Subsequent studies have revealed that HCS is much more important than biotinidase for 
biotinylation of histones in vivo [19, 20, 21, 22], with biotinidase demonstrating histone 
biotinyl transferase activity in vitro [ 20, 23, 24].  HCS functions as a biotin-ligase for 
carboxylases and histones [25]. HCS catalyzes biotinylation of carboxylases and histones 
in a two-step ATPdependent reaction [25]. In the first step, biotinyl 5‟-AMP [B-AMP] is 
generated; in the second step, biotin is transferred from B-AMP to the lysine residue in 
the apocarboxylases and histones [25]. Several histone biotinylation sites have been 
identified using recombinant histone biotin ligases, including HCS and synthetic histone 
tail peptides. The identified biotinylation sites are lysine (K)-9, K13, K125, K127, and 
K129 in histone H2A [26]; K4, K9, K18, and perhaps K23 in histone H3 [20, 24]; and K8 
and K12, and perhaps K5 and K16 in histone H4 [22, 23, 24]. The important role of HCS 
and subsequent biotinylation of histones has been confirmed in various studies. For 
example, phenotypes of HCS knockdown include decreased life span and heat survival in 
Drosophila melanogaster [19], and increased transcriptional activity of retrotransposons 
in metazoans, predisposing test organisms to chromosomal instability [27]. Biotinylation 
of histones has also been shown to play a role in processes such as cell proliferation, gene 
silencing, and the cellular response to UV-induced DNA damage [28, 29].  
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HCS has a dispersed and distinct distribution in chromatin; however its chromatin 
binding sites are poorly defined [19]. Therefore, the objective of this study was to 
generate first insights into HCS binding sites in human chromatin of breast cancer and 
normal breast epithelial cell lines. It was hypothesized that HCS binding sites of the two 
cell lines would be largely similar, as both cell lines are epithelial, with a few variations 
due to the genomic abnormality of the cancer cell line. The investigation was carried out 
using an antibody independent technology as antibody dependent assays demand 
specficity and high cell numbers. Methods that are currently used to study epigenetic 
marks will be described in the following section.  
1.2.3 Chromatin Immunoprecipitation Assay 
 
The chromatin immunoprecipitation [ChIP] assay is a powerful tool for identifying 
proteins, including histone proteins and non-histone proteins, associated with specific 
regions of the genome by using antibodies that specifically recognize the protein/s under 
investigation. The most common approach taken by researchers to study epigenetic 
mechanisms is ChIP assays combined with DNA arrays [7]. ChIP assays together with 
DNA arrays have been demonstrated to successfully map epigenetic marks in the entire 
genome of various species. This procedure is also an excellent tool to map the enzymes 
that mediate epigenetic modifications of DNA and DNA-binding proteins in chromatin.  
Briefly, the following steps are commonly involed with ChIP/DNA array method (Fig. 
1): [1] DNA and proteins in chromatin are cross-linked using formaldehyde, and 
chromatin is sheared to produce fragments of 500–1500 base pairs in size; [2] chromatin 
is immunoprecipitated using an antibody that binds the epigenetic mark of interest; the 
supernatant does not contain the mark of interest and is discarded; [3] DNA is purified 
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from the precipitated chromatin; [4] DNA is chemically labeled [e.g., using fluorophores] 
and is hybridized to DNA microarrays; and [5] the epigenetic mark of interest is mapped 
in the genome, based on its relative enrichment by antibody precipitation [2]. The 
information obtained from the DNA microarray map indicates the relative enrichment of 
a given epigenetic mark in a distinct region of the chromatin. This information can then 
be correlated to transcriptional activity of genes, such as gene upregulation or 
downregulation, and gene silencing, residing in that region.  
 
 
Figure 1: ChIP assay/DNA microarray Methodology [2] 
 
The combination of ChIP assays and DNA microarrays holds great promise for 
the identification of epigenetic modifications and protein involved, but there are also 
various challenges associated with this technology that are discussed below.  A major 
requirement of ChIP assays are antibodies. For each protein or epigenetic mechanism 
under investigation there is a need for an antibody specific for the protein or epigenetic 
mark of interest.  Several common antibodies are commercially available but problem 
19 
 
arises when the antibodies lack specificity or are not commercially available. In both 
situations antibodies have to be synthesized in the lab, which can take anywhere from 
two to four months for polyclonal antibodies, and 8-12 months for monoclonal 
antibodies. Another drawback with ChIP assays is the requirement for large cell numbers 
[in the 10
6–107 range], which limits the applicability of this assay to rare cell samples, 
such as small stem cell batches, oocytes and tissue biopsies that are not available in large 
numbers [3]. Aside from the need for specific antibodies and large cell numbers, there is 
an ethical issue associated with synthesizing antibodies as they are raised in animals that 
are sacrificed at the end of the synthesis process. Finally, a challenge remains with the 
lack of appropriate DNA microarrays. The vast majorities of DNA microarrays contain 
probes for coding regions in genomes but do not contain probes for noncoding regions. 
Noncoding regions contain the majority of regulatory sequences of genes and, hence, are 
the prime target for many epigenetic modifications [7].  
 Therefore, to overcome the problems associated with the ChIP/DNA array 
technique, an antibody-independent technology, specifically DNA adenine 
methyltransfearse identification [DamID] technology, was used in this study to monitor 
HCS in human breast cell lines. This technology would also enable the study of 
chromatin proteins in small cell batches as it is independent of cell number. 
1.2.4 DNA Adenine Methyltransfearse Identification [DamID] Technology  
 
Prior to the development of the DamID technique, it had been demonstrated that a 
DNA cytosine methyltransferase can be targeted in vitro to a pre-determined specific 
DNA sequence by tethering it to a DNA-binding protein, such as zinc finger protein [30]. 
Therefore, it was assessed whether a similar approach could be used to target a 
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Escherichia coli DNA adenine methyltransfearse [Dam] to a specific DNA locus in vivo 
in Drosophila melanogaster [31]. Dam methylates the N6-position of adenine in the 
sequence GATC, which occurs on average every 200–300bp in the fly genome. Dam was 
chosen over other methyltransferases essentially because endogenous methylation of 
adenines is absent in the DNA of most eukaryotes. When expressed in mammalian cells, 
yeast, and Drosophila, Dam has been shown to have no harmful effects on cell viability 
or development [31], in contrast to certain cytosine methyltransferases [31]. DamID 
technology is based on the creation of a fusion protein consisting of Escherichia coli 
DNA adenine methyltransferase [Dam] and a chromatin protein or transcription factor of 
interest.  Upon expression of the fusion protein in cultured cells or in an intact organism 
such as Drosophila, Dam is targeted to the native binding sites of the associated 
chromatin protein resulting in local methylation of adenine residues [1, 31]. Hence, the 
sequences near a binding site of the protein are marked with a unique methylation tag, 
which can be detected using Southern blot-, PCR- and microarray based assays that take 
advantage of restriction enzymes that are methylation sensitive [1].  
With the development of the DamID technology, it became clear that the entire 
human genome could be analyzed for specific DNA-protein interactions and epigenetic 
mechanisms using DamID technology in combination with cDNA or oligonucleotide 
arrays. DamID technique has a number of advantages over other methods that are 
currently used to identify target sequences. First, it eliminates the use of ChIP assays that 
call for large cell numbers and heavily depend on the availability and quality of 
antibodies. Furthermore, it allows for the detection of protein-DNA interactions as they 
occur in living cells unlike ChIP assays that require lysis of cells to obtain chromatin. 
21 
 
ChIP assays also need crosslinking agents that may induce alterations in the chromatin 
structure under investigation leading to identification of unspecific sequences [1, 31]. The 
DamID procedure minimizes the detection of non-target sequences as it has been shown 
that the technique works best when the Dam fusion protein is expressed at very low 
levels, making it unlikely that the fusion protein itself interferes with the functions of the 
endogenous protein or its targets.  
 This study is a proof of principle where feasibility of the DamID technology was 
demonstrated in human mammary epithelial cell lines. For this project, Dam was fused 
with HCS to map the native binding sites of HCS in human breast and breast cancer cell 
genomes in an attempt to identify similarities and differences in the HCS binding regions 
between the two cell lines. HCS-Dam fusion plasmid was expressed in the two cell lines 
using non-viral gene delivery methods.  
1.2.5 Non-Viral Gene Delivery 
 
 Gene delivery is the introduction of exogenous DNA or genes into cells for 
genetic modification. There are several methods to deliver DNA into cells, including viral 
and nonviral techniques [32]. Initial research conducted on gene delivery primarily 
focused on using viral carriers, including both retroviruses and adenoviruses, for gene 
delivery. Viral vectors exhibited high efficiency at delivering both DNA and RNA to 
numerous cell lines [33]. However, fundamental problems associated with viral vector 
systems, including toxicity, immunogenicity, and limitations with respect to scale-up 
procedures, encouraged the investigation of other potential systems, such as non-viral 
gene delivery, to transfer foreign genes into targeted tissue [32].  
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 Nonviral vector systems, including cationic lipids, polymers, dendrimers, and 
peptides, all offer potential ways for compacting DNA for delivery to cells [34]. 
However, unlike viral analogues that have evolved means to overcome cellular barriers 
and immune defense mechanisms, nonviral gene carriers consistently exhibit significantly 
reduced transfection efficiency as they are hindered by numerous extra- and intracellular 
obstacles. However, biocompatibility and potential for large-scale production make these 
compounds increasingly attractive for gene delivery [34]. The most common and 
successful nonviral gene delivery method is complexation with a delivery agent, where 
negatively charged plasmid DNA is condensed through electrostatic interactions with 
cationic lipids to form complexes termed lipoplexes [33, 34] or cationic polymers to form 
polyplexes [35, 36]. Complexation provides the DNA protection from degradation by 
nucleases and other serum components [32] and enhances cellular uptake by reducing the 
effective size of DNA and promoting interactions between positively charged DNA 
complexes and the negatively charged cellular membrane [32]. These complexation 
agents can also facilitate intracellular trafficking, while dissociating from the DNA to 
allow expression [35, 36]. There are two methods in which lipoplexes or polyplexes are 
delivered to cells, including the bolus delivery approach and substrate-mediated gene 
delivery approach. In the conventional bolus delivery approach, cells are first plated on a 
tissue culture substrate and allowed to adhere for a period of 18-20 hours; complexes are 
then added and allowed to diffuse through the bulk media to the cells. In the substrate- 
mediated gene delivery approach, complexes are first immoblized on a tissue culture 
substrate or biomaterial and cells are then seeded on top of the immoblized complexes. 
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The latter approach enhances gene transfer as it elevates DNA concentration within cells 
local microenvironment [].37 
Although the substrate- mediated approach results in enhanced gene transfer, 
bolus delivery is commonly used to transfect cells in order to determine transfection 
efficiencies. Bolus delivery can report on the ability of a cell line to take up foreign DNA, 
and also advises on the need for the substrate-mediated gene delivery approach. If a cell 
line is easily transfected using the bolus delivery approach there is usually no need for 
transfecting cells via substrate-mediated approach. Substrate mediated approach is 
commonly used in studies where higher transfection [>40%] is required or ideal. 
 For this project, the bolus delivery method was first used to deliver a pEGFP-Luc 
reporter gene plasmid complexed with commercially available cationic lipid formations, 
Lipofectamine 2000 and FugeneHD, to human breast and breast cancer cells. The DNA 
to lipid ratio was optimized, to determine the optimum transfection condition, and 
transfection efficiencies were determined. The substrate-mediated approach was not 
utilized for the purposes of this project as bolus delivery resulted in transfection 
efficiencies suitable for the working of Dam fusion plasmids.  
  
24 
 
1.3 Description of Studies 
 
 The purpose of this project was to establish the ability of DamID technology, an 
antibody independent technique, to monitor chromatin protein binding sites in 
mammalian cell lines. This research was conducted in an attempt to eliminate the use of 
ChIP assays in studying DNA-protein interactions in mammalian cell lines. HCS, a 
nuclear protein known to bind to chromosomes [19], was used as a model protein for this 
project. DamID technology was utilized to map the native binding sites of HCS in breast 
cancer and normal breast cells. HCS and HCS-Dam plasmids were cloned, breast cells 
were then transfected with these plasmids using nonviral delivery techniques, genomic 
DNA [gDNA] was isolated, genomic sequences methylated by Dam were digested and 
cloned into the  pBlueScript II sk(+) cloning vector,  which were then further sequenced. 
As the cloning approach was utilized for screening the binding sites, only a few sites 
were revealed. Future studies should utilize microarray technology, such as cDNA 
microarrays, to allow for genome wide analysis of HCS binding sites. Chapter 2 
elaborates on purpose, materials/methods, and results of this project. Chapter 3 highlights 
the conclusion and future of this project. 
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Chapter 2 
Identification of holocarboxylase synthetase chromatin binding sites in human mammary 
cell lines using the DamID technology 
 
Abstract 
 
 Holocarboxylase synthetase (HCS) is a chromatin protein that is essential for 
mediating the covalent binding of biotin to histones. Biotinylation of histones plays 
crucial roles in the repression of genes and repeats in the human genome. We tested the 
feasibility of DNA adenine methyltransferase identification (DamID) technology to map 
HCS binding sites in human mammary cell lines. Full-length HCS was fused to Dam for 
subsequent transfection into breast cancer (MCF-7) and normal breast (MCF-10A) cells. 
HCS docking sites in chromatin were identified by using the unique adenine methylation 
sites established by Dam in the fusion construct; docking sites were unambiguously 
identified using methylation sensitive digestion, cloning, and sequencing. Fifteen novel 
HCS binding sites were identified and included sequences within genes coding for 
inositol polyphosphate-5-phosphatase A, corticotropin hormone precursor, myosin heavy 
chain 9 non-muscle, cadherins 8 and 11, prolactin, leptin precursor, schwannomin 1, 
apoptosis inhibitor, netrin-G1 ligand, neuron navigator, SRY-box4, purinergic receptor, 
and CUB and sushi domains. We conclude that DamID is a useful technology to map 
HCS binding sites in human chromatin and propose that the entire set of HCS binding 
sites could be mapped by combining DamID with microarray technology. 
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2.1 Introduction 
 
Holocarboxylase synthetase (HCS) is a chromatin protein [1] that plays a pivotal 
role in catalyzing histone biotinylation [1, 2]. Biotinylation is unique as it serves as an 
essential metabolic co-factor (biotin) and also functions as a histone modification. 
Initially, it was believed that biotinylation of histones is catalyzed by biotinidase [3]. 
However, subsequent studies revealed that HCS is much more important than biotinidase 
for biotinylation of histones in vivo [1, 4, 5, 6, 7], with biotinidase demonstrating histone 
biotinyl transferase activity in vitro [4, 8, 9]. Histone biotinylation is a recently 
discovered epigenetic mark [10]. Several histone biotinylation sites have been identified 
using recombinant histone biotin ligases, including HCS and synthetic histone tail 
peptides. The identified biotinylation sites are lysine (K)-9, K13, K125, K127, and K129 
in histone H2A [9]; K4, K9, K18, and perhaps K23 in histone H3 [4, 7]; and K8 and K12, 
and perhaps K5 and K16 in histone H4 [8, 11, 7]. In vitro biotinylation of K8, K12, and 
K16 in histone H4 has been confirmed by mass spectrometric analysis of mammalian 
histones [11]. The existence of biotinylated histones was recently questioned [12], but 
three independent laboratories [14, 15, 16], in addition to ours [2, 4, 7, 8, 10, 13], 
confirmed that biotinylation is a natural histone modification. 
 Histone biotinylation is a comparably rare event (<0.1% of histones are 
biotinylated) [10, 14], but the abundance of an epigenetic mark is no marker for its 
importance. For example, only ~3% of cytosines are methylated, but the role of DNA 
methylation in gene regulation is undisputed [17]. Likewise, serine-14 phosphorylation in 
histone H2B and histone poly(ADP-ribosylation) are detectable only after induction of 
apoptosis and major DNA damage, respectively, but the role of these epigenetic marks in 
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cell death is unambiguous [18, 19, 20]. Moreover, low abundance of an epigenetic mark 
in bulk histone extracts compared with its high enrichment at specific loci is consistent 
with regulatory function. Evidence suggests that about one out of three histone H4 
molecules are biotinylated at K12 in telomeric repeats [21]. K12-biotinylated histone H4 
(H4K12bio), K9-biotinylated H3 (H3K9bio), and K18-biotinylated H3 (H3K18bio) are 
enriched at transcriptionally repressed loci in mammalian genomes, suggesting a role for 
histone biotinylation in gene regulation [5, 6, 13, 22]. The important role of HCS and 
subsequent biotinylation of histones has been confirmed in various studies. For example, 
phenotypes of HCS knockdown include decreased life span and heat survival in 
Drosophila melanogaster [1], and increased transcriptional activity of retrotransposons in 
metazoans, predisposing test organisms to chromosomal instability [6].  
HCS has a dispersed and distinct distribution in chromatin, however its chromatin 
binding sites are poorly defined [1]. Therefore, the objective of this study was to adopt 
DNA adenine methyl transferase identification (DamID) technology [23] to generate first 
insights into HCS binding sites in human chromatin, and to pave the way for more 
comprehensive mapping efforts in future studies. Briefly, DamID technology is based on 
fusing DNA adenine methyltransferase (Dam) from Escherichia coli to a chromatin 
protein or transcription factor of interest [23], e.g., HCS.  Upon expression of the fusion 
protein in cultured cells or in an intact organism such as Drosophila, HCS guides Dam to 
HCS binding sites, where Dam creates a unique adenine methylation tag, which is absent 
in most eukaryotes. Adenine methylation sites can be identified by methylation sensitive 
sequencing procedures.   
31 
 
In this proof-of-concept study, DamID technology was used to map, for the first 
time, genomic HCS- binding sites in the human chromatin using mammary epithelial cell 
lines, human breast (MCF-10A) and breast cancer (MCF-7), as aberrant epigenetic marks 
have already been shown in breast cancer cells [24]. 
2.2 Materials and Methods 
 
2.2.1 Cloning HCS-Dam fusion plasmid 
 
The pIND (V5) EcoDam [23, 25] vector was obtained from Dr. Bas van Steensel‟s 
laboratory at the Netherlands Cancer Institute. pIND (V5) EcoDam codes for E.coli Dam, 
and contains a multiple cloning site upstream of the Dam open reading frame. An HCS-
Dam fusion construct was generated as follows. Full-length human HCS was PCR-
amplified using HCS-pET41a as a template [2], AccuPrime™ Pfx DNA polymerase 
SuperMix (Invitrogen, Carlsbad, CA) and the following primers: 5‟-
GTTCGAATTCATGGAAGATAGACTCCACATGG-3‟ (forward, EcoRI site 
underlined) and 5‟-GTTTCTCGAGCCGCCGTTTGGGGAGGATGAGG-3‟ (reverse, 
XhoI site underlined). Following amplification, HCS and pIND (V5) EcoDam vector 
were digested with EcoRI and XhoI (Fermentas, Glen Burnie, MD), ligated using Fast-
Link™ DNA Ligation Kit (Epicenter Biotechnologies, Madison, WI), and transformed 
into MAX Efficiency® DH5α™ Competent Cells (Invitrogen). The HCS-Dam fusion 
plasmid was sequenced (Eurofin MWG Operon, Huntsville, AL) to confirm its identity 
and was denoted “HCS-Dam.” Two control plasmids were used in HCS mapping studies. 
(i) Plasmid pIND V5 EcoDam [23], codes for Dam only and was used to identify 
artifactual binding of Dam to chromatin that was not mediated by HCS. (ii) Plasmid 
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“HCS” codes for full-length human HCS and was used to identify artifactual adenine 
methylation in the absence of Dam. Plasmid HCS was generated as described above for 
HCS-Dam, but the following reverse primer was substituted for the original reverse 
primer: 5‟GTTTTCTAGATTACCGCCGTTTGGGGAGGATGAGG-3‟ (reverse; XbaI 
site underlined). The stop codon in this reverse primer terminates translation after the 
HCS open reading frame.  
2.2.2 Cell culture 
 
MCF-7 and MCF-10A cells (ATCC, Manassas, VA) were used for all studies. MCF-7 
cells were cultured in DMEM/F12 media (ATCC) with the following supplements (v/v): 
1% L-glutamine (Invitrogen), 10% fetal bovine serum (Invitrogen), 1% 
antibiotic/antimycotic (Invitrogen), 1% nonessential amino acids (Invitrogen), and 0.06% 
bovine insulin (Sigma-Aldrich, St. Louis, MO). MCF-10A cells were cultured in 
mammary epithelial growth media (MEGM) + bullet kit (Lonza, Basel, Switzerland), 1% 
(v/v) fetal bovine serum, and 0.05% (v/v) cholera toxin (Sigma-Aldrich).  
2.2.3 Transfection Optimization using Reporter gene pEGFP-Luc 
 
Transfection was optimized using a plasmid containing reporter genes, pEGFP-Luc  
(Clonetech, Mountain View, CA) in MCF-7 and MCF10A cell lines. pEGFP-Luc 
encodes for a fusion of enhanced green fluorescent protein (EGFP) and luciferase (Luc) 
from the firefly Photinus pyralis. Briefly, 20,000 cells/well were seeded in a 48-well 
plate and cells were allowed to adhere for 18 hours. After 18 h, cells were transfected 
with pEGFP-LUC-transfection reagent complexes formulated in serum-free opti-MEM 
media (Invitrogen). For MCF-7 cells, pEGFP-Luc was complexed with Lipofectamine 
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(LF) 2000 (Invitrogen,) and the complexes were incubated for 20 min. For MCF10A 
cells, pEGFP-Luc was complexed with FugeneHD (Roche, Madison, WI) and the 
complexes were allowed to incubate for 15 minutes. After incubation, complexes were 
delivered to the two cell lines. Cells were assayed for EGFP expression using 
fluoroescence microscopy (Leica DMI 3000B, Bannockburn, IL) at 24 and 48 h post-
transfection. At 48 h, cells were lysed and cell lysate was assayed for luciferase 
expression, using the Luciferase Assay System (Promega, Madison, WI) and a 
luminometer (Turner Biossytem, Sunnyvale, CA), which returned luciferase activity in 
RLUs (Relative Light Units). Luciferase activity was normalized to the total protein 
amount, in the cell lysate, determined with the BCA protein assay (Pierce, Rockford, IL) 
and transfection levels were reported as RLUs/mg of protein. Each transfection 
experiment was performed in duplicate. 
DNA (pEGFP-Luc) amount and DNA to transfection reagent ratio was varied to 
determine an optimum transfection condition for both cell types. Conditions were 
optimized based on the following factors i) transfection efficiency (percentage of EGFP-
positive cells assayed by fluorescence microscopy); ii) gene activity (RLUs/mg of 
protein); and iii) cell viability and morphology (analyzed through phase microscopy 
using Leica DMI 3000B). 
2.2.4 Transfection of cells with HCS-Dam and control plasmids 
 
For transfection with HCS-Dam, EcoDam and HCS plasmids, 3.5 x 10
6
 cells were 
seeded in T-75 flasks and allowed to adhere for 18 h, after which time cells were 
transfected with one of the three plasmids as follows. DNA was complexed with 
Lipofectamine (LF) 2000 (Invitrogen) or FugeneHD (Roche) in serum-free opti-MEM 
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media (Invitrogen). For MCF-7 cells, 6.75 µg of each plasmid was complexed with 10.2 
µl of LF 2000 in a 1:1.5 DNA to lipid ratio (µg of DNA to µl of LF2000). These 
complexes were allowed to incubate for 20 min and were then added to each designated 
flask. For MCF-10A cells, 8.25 µg of each plasmid was complexed with 20.625 µl of 
FugeneHD in a 1:2.5 DNA to Fugene ratio (µg of DNA to µl of FugeneHD). These 
complexes were incubated for 15 min and were then delivered to each designated flask. 
Forty-eight hours after transfection, cells were collected and lysed using protocols 
specific for isolation of RNA or genomic DNA.  
2.2.5 Quantitative Real-time PCR (qRT-PCR) 
 
Total RNA was collected using the RNeasy mini kit (Qiagen, Valencia, CA) and 
reverse transcribed using the ImProm-II Reverse Transcription System (Promega). The 
cDNA was used to confirm successful transfection of cells with plasmids HCS-Dam, 
EcoDam, and HCS, using the following primers and SYBR green (Qiagen) in qRT-PCR 
expression analysis: (i) HCS-Dam =  5‟-GCAACTCCTTCGACATGCTGAGAAA-3‟ 
(forward, positioned in HCS region) and  5‟-TCTTCATGCCGGTACGCGTAGAAT-3‟ 
(reverse, positioned in Dam region); (ii) Dam = 5‟-
TCTGGTTGAGCGCCATATTCCAGT-3‟ (forward) and 5‟-
TGTACAAAGCCAGCAGTTCGTCCA-3‟ (reverse); and (iii) HCS = 5‟-
ATGGAAGATAGACTCCACAT-3‟ (forward) and 5‟-
TGAGACCTGATCCTTAACTTCC-3‟ (reverse). Glyceraldehyde 3-phosphate 
dehydrogenase was used as the reference gene for qRT-PCR normalization, using primers 
5‟-TCCACTGGCGTCTTCACC-3‟ (forward) and 5‟-GGCAGAGATGATGACCCTTT-
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3‟ (reverse) [6]. The cycle threshold values were used to calculate amplicon abundance 
[31]. 
2.2.6 Mapping HCS-binding sites of adenine-methylated Sequences 
 
Genomic DNA was purified 48 h after transfection by using the DNeasy mini kit 
(Qiagen). DNA was digested with DpnI (Fermentas, Glen Burnie, MD), which is 
sensitive to adenine methylation. The digested fragments were purified using a PCR 
purification kit (Qiagen) and ligated into the pBlueScript II sk(+) vector after 
linearization with BamHI (Fermentas); the Fast-Link™ DNA Ligation Kit was used for 
ligation. Note that digestion with DpnI and BamHI produces compatible overlaps. The 
ligation mixture was transformed into MAX Efficiency® DH5α™ Competent Cells and 
the cells were plated on LB-Ampicillin plates. White colonies were randomly selected for 
sequencing by using the T7 promoter primer (Eurofins MWG Operon, Huntsville, AL). 
2.2.7 Statistics 
 
 The GraphPad Prism 5.0 program (La Jolla, CA) was used to plot transfection 
optimization and qRT-PCR graphs. Data are presented as the mean ± SEM. Multiple 
comparisons were evaluated by one-way ANOVA, followed by post hoc Tukey test. 
Values were considered statistically significant if P < 0.05. 
 
2.3. Results and Discussion 
 
2.3.1 Transfection Optimization 
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Work in Drosophila [26] suggests that it is important to keep the expression level 
of Dam-fusion proteins very low to avoid saturating methylation levels [23]. The pIND 
(V5) EcoDam vector consists of an inducible promoter; however it has been shown that 
leaky expression of Dam fusion plasmids is sufficient for specific methylation of target 
sequences [26, 27]. Induction of the vector leads to high background methylation, which 
makes the identification of target sequences difficult [27]. Ideally a transfection 
efficiency of 30% or higher is needed for transient transfection with Dam fusion proteins 
[27], although good binding maps have also been obtained with lower efficiency 
transfections [27]. Transfection was hence optimized using pEGFP-Luc reporter plasmid 
in the two breast cell lines in order to determine the maximum transfection or expression 
level that could be achieved with adequate cell viability.  It was found that 0.11 µg of 
pEGFP-Luc in a 1:1.5 DNA: LF2000 ratio was the optimum transfection condition for 
MCF-7 cells. This condition resulted in 16 ± 3.5 % transfection efficiency (Fig. 2A) and 
a luciferase activity of 3× 10
9
 RLUs/mg of protein (Fig. 2B).  Similarly, for MCF-10A 
cells, 0.11 µg of pEGFP-Luc using 1:2.5 DNA to FugeneHD ratio was determined to be 
the optimum condition. This condition resulted in 29 ± 2.4% transfection efficiency (Fig. 
3A) and a luciferase activity of 4× 10
9
 RLUs/mg of protein (Fig. 3B). The optimal 
conditions were then used for the DamID experiments. Although, transfection efficiency 
was less than the desired 30% for MCF-7 cells, expression of Dam plasmids were 
confirmed, in vitro, using qRT-PCR (results discussed below), prior to the conduction of 
the DamID assay. 
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Figure 2. Complex conditions (DNA to transfection reagent ratio and DNA amount) used 
for transfection in MCF-7 cells used for DamID assays were selected based on 
optimization of transfection conditions in which ratio and DNA amounts were compared 
to transfection efficiency (percentage of EGFP-positive cells) (A) and luciferase gene 
activity (B). This figure represents an optimum ratio of 1:1.5 DNA: LF 2000 at different 
pEGFP-Luc concentrations. Each bar represents the mean + SEM, n = 2. 
a,b,c, d
Bars with 
different letters indicate significant differences (P < 0.05) between treatments. 
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Figure 3. Complex conditions (DNA to transfection reagent ratio and DNA amount) used 
for transfection in MCF-10A cells used for DamID assays were selected based on 
optimization of transfection conditions in which ratio and DNA amounts were compared 
to transfection efficiency (percentage of EGFP-positive cells) (A) and luciferase gene 
activity (B). This figure represents an optimum ratio of 1:2.5 DNA: Fugene at different 
pEGFP-Luc concentrations. Each bar represents the mean + SEM, n = 2. 
a,b,c
Bars with 
different letters indicate significant differences (P < 0.05) between treatments. 
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2.3.2 Plasmid expression 
 
 Transfection of mammary cells with plasmids Dam-HCS, EcoDam, or HCS 
produced the expected expression patterns compared with non-transfected control cells. 
When cDNA was analyzed using PCR primers for HCS, the transcript abundance was 
170-fold and 62-fold greater in MCF-7 cells transfected with HCS and HCS-Dam, 
respectively, than in non-transfected control cells (Fig. 4A); the abundance of HCS 
transcript was not altered by transfection with EcoDam (negative control) as it did not 
contain HCS. When cDNA was analyzed using PCR primers for the HCS-Dam fusion 
protein, the transcript abundance was 2000-fold greater in MCF-7 cells transfected with 
HCS-Dam than in non-transfected control cells (Fig. 4B); the abundance of HCS-Dam 
fusion transcript was not altered by transfection with EcoDam and HCS (negative 
controls) as these controls lacked HCS-Dam fusion. When cDNA was analyzed using 
PCR primers for Dam, the transcript abundance was 660-fold and 800-fold greater in 
MCF-7 cells transfected with EcoDam and HCS-Dam, respectively, than in non-
transfected control cells (Fig. 4C); the abundance of Dam transcript was not altered by 
transfection with HCS (negative control) as it did not contain Dam. Results were 
comparable in MCF-10A cells (Fig. 5).
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Figure 4. Transcript abundance in MCF-7 cells transfected with plasmids HCS-Dam, 
EcoDam and HCS. Transcripts were quantified by qRT-PCR using gene-specific primers 
for HCS (A), HCS-Dam fusion (B), and EcoDam (C). Each bar represents the 
mean + SEM, n = 3. 
a,b,c
Bars with different letters indicate significant differences 
(P < 0.05) between treatments.
A B 
C 
40 
 
 
C
on
tr
ol
E
co
D
am
H
C
S
H
C
S
-D
am
0
200
400
600
800
a a
b
c
Plasmid
m
R
N
A
 A
b
u
n
d
a
n
c
e
(A
rb
it
ra
ry
 U
n
it
s
)
C
on
tr
ol
E
co
D
am
H
C
S
H
C
S
-D
am
0
20000
40000
60000
80000
a a a
b
Plasmid
m
R
N
A
 A
b
u
n
d
a
n
c
e
(A
rb
it
ra
ry
 U
n
it
s
)
C
on
tr
ol
E
co
D
am
H
C
S
H
C
S
-D
am
0
2000
4000
6000
8000
a a
b
c
Plasmid
m
R
N
A
 A
b
u
n
d
a
n
c
e
(A
rb
it
ra
ry
 U
n
it
s
)
 
Figure 5. Transcript abundance in MCF-10A cells transfected with plasmids HCS-Dam, 
EcoDam and HCS. Transcripts were quantified by qRT-PCR using gene-specific primers 
for HCS (A), HCS-Dam fusion (B), and EcoDam (C). Each bar represents the 
mean + SEM, n = 3. 
a,b,c
Bars with different letters indicate significant differences 
(P < 0.05) between treatments.
A B 
C 
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2.3.3 HCS-docking sites 
 
Following the validation of expression of fusion and control plasmids, these 
plasmids were expressed in MCF-7 and MCF-10A cell lines, genomic sequences 
methylated by Dam were cloned into the  pBlueScript II sk(+) cloning vector,  positive 
clones were obtained and sequenced. When five clones from HCS-Dam positive MCF-7 
cells were annotated by NCBI‟s basic local alignment search tool (BLAST), seven unique 
HCS-binding sequences, within specific genes, were detected (Table 1). Each clone 
returned more than one sequence, because of the complimentary ends created during 
digestion with DpnI and the random ligation of these fragments during ligation and 
cloning.  Transfection with plasmid HCS (negative control) did not produce any clones in 
MCF-7 cells. We conclude that HCS greatly enhances the binding of Dam at distinct 
genomic loci. Results in MCF-10A cells were comparable to those in MCF-7. Five clones 
from HCS-Dam positive MCF-10A cells detected eight unique sequences when annoted 
by BLAST, (Table 2).  
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Table 1 
Genomic HCS binding sites in MCF-7 cells.  
MCF-7  
HCS-Binding Loci 
Genes Chromosome GenBank 
Acession 
Number 
5‟-
CCACAGAATCAGGGGATAACG 
CAGGAAAGAACAT- 3‟ 
Inositol 
polyphosphate-5-
phosphatase A 
 
10 
 
NM_00553
9.3 
 
5‟- 
CAGGAAAGAACATGTGAGCAA
AAG- 3‟ 
  
 
Corticotropin 
releasing hormone 
precursor (CRH), 
and 
Homolog of yeast 
ribosome biogenesis 
regulatory protein 
(RRS1) 
 
 
8 
 
 
NM_0007
56.2 
NM_0151
69.3  
 
 
5‟-
ATAGCTCACGCTGTAGGTATCT
CAGTTCGGTGTA- 3‟ 
 
Cadherin 8 and, 
Cadherin 11 
Type2 preproproteins 
 
 
 
16 
NM_0017
96.2 
NM_0017
97.2 
 
  
5‟-
ACCATGCTCTTTCCCCCTTGCA
ACCTCACTCATTCTCTCTCCTA
TTC- 3‟ 
 
 
Schwannomin 
interacting protein 1 
(SCHIP1) 
 
3 
 
NM_0145
75.2 
5‟-
GGTTTTTATCTTTGCAAGCAGC 
AGAT-3‟ 
Neuron navigator 3 
(NAV3) 
 
 
12 NM_0149
03.4 
5‟- 
ATTCCACACAACATACGAGC-3‟ 
 
Leptin precursor 
 
7 NM_0002
30.2 
5‟-
AAAGGGATTTTGGGGCATGAG
ATCATC- 3‟ 
 
Apoptosis inhibitor 5 
isoform b 
 
11 NM_0065
95.3 
5‟-
AAAGGGATTTTGGGGCATGAG
ATCATC- 3‟ 
 
Netrin-G1 ligand 11 NM_0209
29.1 
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Table 2 
Genomic HCS binding sites in MCF-10A cells.  
MCF-10A 
HCS-Binding Loci 
Genes Chromosome GenBank 
Acession 
Number 
5‟-
CCACAGAATCAGGGGATAACG 
CAGGAAAGAACAT- 3‟ 
Inositol 
polyphosphate-5-
phosphatase A 
 
10 
 
NM_00553
9.3 
5‟-
TCGCCCTATAGTGAGTCGTAT- 
3‟   
  
  
 
Homo sapiens 
myosin, heavy chain 
9, non-muscle 
(MYH9) 
 
22 
 
NM_0024
73.4 
5‟-
CAGGAAAGAACATGTGAGCAA
AAG- 3‟ 
  
 
Corticotropin 
releasing hormone 
precursor 
(CRH), and  
 Homolog of yeast 
ribosome biogenesis 
regulatory protein 
(RRS1) 
       
 
8 
 
NM_0007
56.2 
NM_0151
69.3  
 
 
 
5‟-
TGAGCTAACTCACATTAATTGC
GTTG- 3‟ 
 
SRY (sex 
determining region 
Y)-box 4, and 
Prolactin 
 
 
6 
 
NM_0031
07.2 
NM_0011
63558.1 
 
5‟- 
CCTGTTTTGCAGGGTGCTTT- 3‟  
 
 
Purinergic receptor  
P2X5 isoform A and 
B 
 
 
 
 
 
17 
 
NM_0025
61.2 
5‟- 
GAGCTCCAGCTTTTTTTCTCTT
TAG- 3‟ 
 
Tetratricopeptide 
repeat domain 7B 
 
14 XM_5101
18.2 
5‟- 
CCTGGGGTGCCTAATGAGTG- 
3‟ 
 
CUB and Sushi 
multiple domains 1 
 
8 Q96PZ7-1 
5‟- 
ATTCCACACAACATACGAGC- 
3‟ 
 
Leptin precursor 
 
7 NM_0002
30.2 
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Please also note the following observations. First, when MCF-10A cells were 
transfected with plasmid HCS, one clone with one single sequence was identified 
compared with the seven clones in cells transfected with HCS-Dam, indicating that the 
false positive rate due to these artifacts might be up to 14% in Dam-based assays. 
Second, for the MCF-10A cell line, a locus within X-linked neuroligin4 gene was 
disregarded as a potential HCS docking site, as it appeared due to artefactual methylation 
by pIND (V5) EcoDam control. No such artifactual methylation by Dam was observed 
for MCF-7 cells. Third, four HCS-docking sites were found to be common between 
MCF-7 and MCF-10A cells, indicating a 28% overlap in the HCS binding regions 
identified  in the two epithelial cell lines, further increasing confidence that the results 
produced by HCS-Dam technology are real. Note that clones were selected randomly in 
this proof-of-concept study and, therefore, one must not expect a 100% overlap in clones. 
Comprehensive maps can only be generated by using microarray-based technologies or 
high-throughput sequencing and may show an expected overlap of 100% between the 
identified genes, as both cell lines used in this study are of epithelial origin or 
alternatively could allow for determination of non-overlapping loci specific for either cell 
type. Also note that the following gene sets share a common HCS-docking locus: CRH 
and RRS1 (Tables 1 and 2), cadherin 8 and cadherin 11 (Table 1) and, SRY-box4 and 
prolactin (Table 2).  
  The overlapping HCS binding regions were found within four genes: INPP5A on 
chromosome 10, and CRH and RRS1 on chromosome 8, and leptin precursor on 
chromosome 7. INPP5A is a member of the INPP enzyme family [28, 29]. INPPs 
regulate diverse cellular processes such as protein trafficking, phagocytosis, and synaptic 
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vesicle recycling [29]. Loss of genetic material in the chromosome that includes INPP5A 
has been associated with brain tumors and leukemia [30]. It has also been demonstrated 
that loss or lower expression of INPP5 is an early mechanism in the development of 
cutaneous squamous cell carcinoma [30]. Similarly, CRH is a polypeptide hormone and 
is involved in stress response [31]. CRH has been implicated
 
in various stress-induced 
abnormalities, including changes in
 
both human and rat gastrointestinal functions such as 
motility
 
and gastric acid secretion [31]. CRH gene has been shown to be highly expressed 
in MCF-7 cells [32], thus providing the basis to postulate a mechanism according to 
which CRH is secreted by tumor cells and exerts local – paracrine or autocrine – 
inhibitory action over breast cell growth [32]. Also, on chromsome 8, a locus of ribosome 
biogenesis regulatory protein (RRS1) was determined to be HCS-docking site in the two 
breast cell lines. RRS1 has been shown to regulate ribosome biosynthesis pathway in 
growing cells [33]. Leptin precursor gene, on chromosome 7, is known to be an integral 
component of a physiological signalling
 
system that regulates fuel stores and energy 
balance in specific areas of the brain [34].The finding that INPP5A, CRH, RRS1, and 
leptin precursor genes possess potential HCS binding sites in human breast tissues 
underlines their importance in the interactions with the chromatin that further lead to 
biotinylation of histone proteins.  
 This study proves feasibility of the DamID technology to identify, for the first 
time, potential HCS binding sites in human mammary epithelial cell lines. DamID 
technology eliminates the need for large cell numbers and antibodies and thus represents 
a viable alternative method to the chromatin immunoprecipitation (ChIP) assay, a 
frequently used tool to investigate DNA-chromatin interactions. With the establishment 
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of the abilty of DamID technology to identify chromatin protein binding sites, the future 
goal of this project is to use the technology along with cDNA microarray sequencing to 
monitor chromatin proteins in small cell samples, such as oocytes. While the combination 
of techniques employed in this study only provided a snapshot of events occurring at the 
genomic level, it proves the DamID technology‟s utility and when combined with 
microarray sequencing, has the potential for full genome analysis.
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Chapter 3 
Conclusions and Future Goals 
 
3.1 Introduction  
 
Studies conducted in this project verified the DNA adenine methyl transferase 
identification (DamID) technology in human breast (MCF-10A) and breast cancer (MCF-
7) cell lines (Chapter 2). The technology was successfully used to map the binding sites 
of holocarboxylase synthetase (HCS) chromatin protein in MCF-7 and MCF-10A cells. 
Fifteen novel HCS binding sites were identified and included sequences within genes 
coding for inositol polyphosphate-5-phosphatase A, corticotropin hormone precursor, 
myosin heavy chain 9 non-muscle, cadherins 8 and 11, prolactin, and several others.  
While it was shown in this study that DamID technology can be employed to investigate 
chromatin proteins in human breast tissues, the future goal of this project is to study 
chromatin proteins and epigenetic marks in oocytes that are artificially cultured for the 
purpose of assisted reproductive technology (ART). DamID was established in this 
project because more traditional and commonly used chromatin immunoprecipitation 
(ChIP) assays require large cell numbers (typically in the 10
6–107 range) and highly 
specific antibodies [1, 2]. ChIP assays, therefore, cannot be utilized for studying 
chromatin in oocytes as they are hard to obtain in large batches. In addition, DamID 
technology has several other advantages over ChIP assays. It eliminates the need for 
target-specific antibodies making the investigation of any chromatin protein, such as 
DNA methyltransferases and histone acetyltransferases, relatively easy. Unlike ChIP 
assays, DamID technology also allows for the detection of protein-DNA interactions as 
they occur in living cells and does not require cell lysis to acquire the chromatin [3]. As 
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opposed to the DamID technology, ChIP assays also require crosslinking agents that can 
induce alterations in the chromatin structure under investigation leading to the 
identification of unspecific-target sequences [3].   
3.2 Assisted Reproductive Technology (ART) and Birth Defects 
 
 According to 1992 Fertility Clinic Success Rate and Certification Act, ART is 
defined as fertility treatments in which both eggs or oocytes and sperms are handled in 
the laboratory [4]. Although the use of ART has become a widely accepted and 
implemented therapy for some forms of infertility, there have been concerns about the 
long-term safety of removing and handling germline cells [4]. Studies conducted between 
the years 1991-1998 demonstrate a correlation between ART and low birth weight 
(LBW) and multiple births [5, 6, 7]. Since low birth weight is in part epigenetically 
controlled, an epigenetic connection seems plausible for birth defects in ART population 
[4].  
Several human disorders involving birth defects have now been shown to be 
caused by epigenetic alterations. The cardinal features of Beckwith-Wiedemann 
syndrome (BWS), which is linked to a cluster of imprinted genes on chromosme 11p15.5, 
are prenatal overgrowth, abdominal wall defects, neonatal hypoglycemia, and 
macroglossia [4]. Prader-Willi syndrome, which is linked to a cluster of imprinted genes 
on chromosome 15p11-13 normally expressed from the paternal allele, is characterized 
by muscular hypotonia, obesity, mental retardation, and hypogonadotrophic 
hypogonadism. Another neurological birth defect syndrome, Angelman syndrome (AS), 
is also linked to chromosome 15p11-13; in this case, to a gene normally expressed from 
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the maternal allele. The characteristic features of AS include severe developmental delay, 
absent speech, seizures, ataxia, hyperreflexia, and hypotonia [4]. Genetic mutations of the 
epigenetic machinery also cause birth defects. Rett syndrome is caused by mutations in 
the X-linked gene encoding MeCP2, a methyl-CpG-binding protein [4].  
The cause of the link between ARTs and epigenetic alterations
 
is currently 
unknown. It could be due to some aspect of the
 
ARTs techqniue. There is a wide range of 
different ARTs, such as in vitro fertilization, which
 
are now routinely used within clinics. 
Techniques utilized for ART, duration of artificial culture, and mechanical manipulation 
can expose
 
one or both of the germ cells to an altered hormonal regime [8].
 
Any 
alterations to the normal environment of the oocyte
 
or sperm could result in changes to 
some aspect of their imprinting
 
mechanisms [8]. For example, studies in humans and 
mice suggest that superovulation can lead to the production of oocytes without their 
correct primary imprint, and aberrant DNA methylation [9]. It is unclear whether the 
cause is hormonal stimulation, gamete manipulation, or culture conditions [8].
 
It has been 
suggested that in vitro culture of gametes, zygotes,
 
and embryos, representing a common 
feature of all ART techniques,
 
results in an accumulation of epigenetic alterations leading
 
to an enhancement in fetal growth and heavier newborn cattle,
 
known as large offspring 
syndrome [8].   
Evidences mentioned above suggest a link between artificial culture of oocytes, 
used in ART, and aberrant epigenetics and birth defects. Therefore the future goal of this 
project is to establish biotinylation marks in artificially manipulated mice oocytes, before 
proceeding on to human oocytes. Biotinylation is a recently discovered epigenetic mark 
and is mediated by HCS chromatin protein [10]. Genomic binding sites of HCS would be 
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mapped in artificially cultured oocytes, using the DamID technology. This work would 
lay the foundation for succeeding studies where the aberrancy and normalcy of 
biotinylation marks in cultured oocytes, prior to fertilization, would be investigated. 
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